Abstract
To explore the effects of lipoprotein(a) (Lp(a)) and fibrinogen (Fib) in senior patients with coronary heart disease (CHD) and examine the relationship of Lp(a) and Fib. Based upon the results of coronary artery angiography (CAG), 784 subjects aged over 65 years were divided into control (n = 116) group, one-vessel (n = 106) group, two-vessel (n = 120) and three-vessel (n = 442) groups. And the levels of Lp(a) and Fib were measured. (1) With increasing number of involved branches, the level of Lp(a) gradually rose in male group ((0.22 ± 0.16), (0.28 ± 0.23), (0.32 ± 0.19), (0.34 ± 0.21) g/L; F = 9.22, P < 0.01); (2) whether for males or females, with increasing number of involved branches, the levels of Fib gradually rose in male group ((3.24 ± 0.82), (3.41 ± 0.82), (3.45 ± 0.89), (3.61 ± 0.90) g/L; F = 3.09, P < 0.05) and in female group ((3.58 ± 0.97), (3.69 ± 1.20), (3.77 ± 0.88), (4.09 ± 1.05) g/L; F = 4.34, P < 0.01); (3) the level of Lp(a) had a positive correlation with Fib in male group (r = 0.15, P < 0.01); (4) multi-Logistic regression analysis showed that Lp(a) and Fib were influencing factors of CHD (OR = 0.31, 1.32, both P < 0.05). There are significant correlations between Lp(a), Fib and the severity of CHD in senior male patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
